Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 2/20 | 0.34 |
| ▸ | DRD1 | P21728 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.33 |
| ▸ | HTR6 | P50406 | 1/20 | 0.33 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10515155 | 0.81 | MAOA (0.40) | HRH3DRD2DRD1CHRM3 | |
| SCHEMBL14930410 | 0.81 | PNMT (0.41) | PNMTHRH3CYP3A4TSHRHSD17B10 | |
| SCHEMBL23109907 | 0.80 | PNMT (0.40) | PNMTHRH3CYP3A4TSHRHSD17B10 | |
| SCHEMBL14925529 | 0.79 | PNMT (0.39) | PNMTHRH3CYP3A4TSHRHSD17B10 | |
| SCHEMBL10853682 | 0.73 | PNMT (0.38) | PNMTHRH3CYP3A4ABCB1 | |
| SCHEMBL10513652 | 0.69 | MAOA (0.38) | CYP3A4DRD2DRD1CHRM3HTR6 | |
| SCHEMBL10514356 | 0.67 | DRD2 (0.42) | CYP3A4DRD2CHRM3HTR6ABCB1 | |
| SCHEMBL10524531 | 0.67 | KDM4E (0.40) | DRD2DRD1 | |
| SCHEMBL10511990 | 0.65 | MAOA (0.37) | DRD2DRD1 | |
| SCHEMBL6369684 | 0.65 | CA2 (0.48) | PNMTHRH3DRD2DRD1ABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200062769-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | GENENTECH, INC. (US) | 2020-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200062769-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | PDXK, BTK, TYK2 | PNMT 1349/4885HRH3 529/4885CYP3A4 932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.